世界の好酸球性食道炎薬市場2020-2025:ブデソニド、フルチカゾン、その他

【英語タイトル】Global Eosinophilic Esophagitis Drug Market Growth 2020-2025

LP Informationが出版した調査資料(LPI20AP4955)・商品コード:LPI20AP4955
・発行会社(調査会社):LP Information
・発行日:2020年3月4日
・ページ数:159
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,660 ⇒換算¥417,240見積依頼/購入/質問フォーム
Multi UserUSD5,490 ⇒換算¥625,860見積依頼/購入/質問フォーム
Corporate UserUSD7,320 ⇒換算¥834,480見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「好酸球性食道炎薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、ブデソニド、フルチカゾン、その他など、用途別には、病院、クリニック、ドラッグストアなどに区分してまとめた調査レポートです。好酸球性食道炎薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・好酸球性食道炎薬の世界市場概要(サマリー)
・好酸球性食道炎薬の企業別販売量・売上
・好酸球性食道炎薬の企業別市場シェア
・好酸球性食道炎薬の世界市場規模 2015年-2020年:種類別(ブデソニド、フルチカゾン、その他)
・好酸球性食道炎薬の世界市場規模 2015年-2020年:用途別(病院、クリニック、ドラッグストア)
・好酸球性食道炎薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・好酸球性食道炎薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・好酸球性食道炎薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・好酸球性食道炎薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・好酸球性食道炎薬市場の成長要因・課題・動向
・好酸球性食道炎薬の世界市場予測 2021年-2025年
・好酸球性食道炎薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・好酸球性食道炎薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・好酸球性食道炎薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・好酸球性食道炎薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・好酸球性食道炎薬の世界市場予測:種類別(ブデソニド、フルチカゾン、その他)
・好酸球性食道炎薬の世界市場予測:用途別(病院、クリニック、ドラッグストア)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Eosinophilic Esophagitis Drug market will register a 5.7% CAGR in terms of revenue, the global market size will reach $ 141.8 million by 2025, from $ 113.6 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Eosinophilic Esophagitis Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Esophagitis Drug market by type, application, key manufacturers and key regions and countries.

This study considers the Eosinophilic Esophagitis Drug value and volume generated from the sales of the following segments:

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Budesonide
Fluticasone
Others

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospitals
Clinics
Drugstore

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
Celgene
GSK
Adare Pharmaceuticals
DBV Technologies
Bayer
Takeda
Dr. Falk Pharma
Calypso
Quorum Innovations
Regeneron

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Eosinophilic Esophagitis Drug consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Eosinophilic Esophagitis Drug market by identifying its various subsegments.
Focuses on the key global Eosinophilic Esophagitis Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Eosinophilic Esophagitis Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Eosinophilic Esophagitis Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Eosinophilic Esophagitis Drug Consumption 2015-2025
2.1.2 Eosinophilic Esophagitis Drug Consumption CAGR by Region
2.2 Eosinophilic Esophagitis Drug Segment by Type
2.2.1 Budesonide
2.2.2 Fluticasone
2.2.3 Others
2.3 Eosinophilic Esophagitis Drug Consumption by Type
2.3.1 Global Eosinophilic Esophagitis Drug Consumption Market Share by Type (2015-2020)
2.3.2 Global Eosinophilic Esophagitis Drug Revenue and Market Share by Type (2015-2020)
2.3.3 Global Eosinophilic Esophagitis Drug Sale Price by Type (2015-2020)
2.4 Eosinophilic Esophagitis Drug Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Drugstore
2.5 Eosinophilic Esophagitis Drug Consumption by Application
2.5.1 Global Eosinophilic Esophagitis Drug Consumption Market Share by Type (2015-2020)
2.5.2 Global Eosinophilic Esophagitis Drug Value and Market Share by Type (2015-2020)
2.5.3 Global Eosinophilic Esophagitis Drug Sale Price by Type (2015-2020)

3 Global Eosinophilic Esophagitis Drug by Company
3.1 Global Eosinophilic Esophagitis Drug Sales Market Share by Company
3.1.1 Global Eosinophilic Esophagitis Drug Sales by Company (2018-2020)
3.1.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Company (2018-2020)
3.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Company
3.2.1 Global Eosinophilic Esophagitis Drug Revenue by Company (2018-2020)
3.2.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Company (2018-2020)
3.3 Global Eosinophilic Esophagitis Drug Sale Price by Company
3.4 Global Eosinophilic Esophagitis Drug Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Eosinophilic Esophagitis Drug Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Eosinophilic Esophagitis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Eosinophilic Esophagitis Drug by Regions
4.1 Eosinophilic Esophagitis Drug by Regions
4.2 Americas Eosinophilic Esophagitis Drug Consumption Growth
4.3 APAC Eosinophilic Esophagitis Drug Consumption Growth
4.4 Europe Eosinophilic Esophagitis Drug Consumption Growth
4.5 Middle East & Africa Eosinophilic Esophagitis Drug Consumption Growth

5 Americas
5.1 Americas Eosinophilic Esophagitis Drug Consumption by Countries
5.1.1 Americas Eosinophilic Esophagitis Drug Consumption by Countries (2015-2020)
5.1.2 Americas Eosinophilic Esophagitis Drug Value by Countries (2015-2020)
5.2 Americas Eosinophilic Esophagitis Drug Consumption by Type
5.3 Americas Eosinophilic Esophagitis Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Eosinophilic Esophagitis Drug Consumption by Regions
6.1.1 APAC Eosinophilic Esophagitis Drug Consumption by Regions (2015-2020)
6.1.2 APAC Eosinophilic Esophagitis Drug Value by Regions (2015-2020)
6.2 APAC Eosinophilic Esophagitis Drug Consumption by Type
6.3 APAC Eosinophilic Esophagitis Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Eosinophilic Esophagitis Drug by Countries
7.1.1 Europe Eosinophilic Esophagitis Drug Consumption by Countries (2015-2020)
7.1.2 Europe Eosinophilic Esophagitis Drug Value by Countries (2015-2020)
7.2 Europe Eosinophilic Esophagitis Drug Consumption by Type
7.3 Europe Eosinophilic Esophagitis Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Eosinophilic Esophagitis Drug by Countries
8.1.1 Middle East & Africa Eosinophilic Esophagitis Drug Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Eosinophilic Esophagitis Drug Value by Countries (2015-2020)
8.2 Middle East & Africa Eosinophilic Esophagitis Drug Consumption by Type
8.3 Middle East & Africa Eosinophilic Esophagitis Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Eosinophilic Esophagitis Drug Distributors
10.3 Eosinophilic Esophagitis Drug Customer

11 Global Eosinophilic Esophagitis Drug Market Forecast
11.1 Global Eosinophilic Esophagitis Drug Consumption Forecast (2021-2025)
11.2 Global Eosinophilic Esophagitis Drug Forecast by Regions
11.2.1 Global Eosinophilic Esophagitis Drug Forecast by Regions (2021-2025)
11.2.2 Global Eosinophilic Esophagitis Drug Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Eosinophilic Esophagitis Drug Forecast by Type
11.8 Global Eosinophilic Esophagitis Drug Forecast by Application

12 Key Players Analysis
12.1 AstraZeneca
12.1.1 Company Information
12.1.2 Eosinophilic Esophagitis Drug Product Offered
12.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 AstraZeneca Latest Developments
12.2 Celgene
12.2.1 Company Information
12.2.2 Eosinophilic Esophagitis Drug Product Offered
12.2.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Celgene Latest Developments
12.3 GSK
12.3.1 Company Information
12.3.2 Eosinophilic Esophagitis Drug Product Offered
12.3.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GSK Latest Developments
12.4 Adare Pharmaceuticals
12.4.1 Company Information
12.4.2 Eosinophilic Esophagitis Drug Product Offered
12.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Adare Pharmaceuticals Latest Developments
12.5 DBV Technologies
12.5.1 Company Information
12.5.2 Eosinophilic Esophagitis Drug Product Offered
12.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 DBV Technologies Latest Developments
12.6 Bayer
12.6.1 Company Information
12.6.2 Eosinophilic Esophagitis Drug Product Offered
12.6.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Bayer Latest Developments
12.7 Takeda
12.7.1 Company Information
12.7.2 Eosinophilic Esophagitis Drug Product Offered
12.7.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Takeda Latest Developments
12.8 Dr. Falk Pharma
12.8.1 Company Information
12.8.2 Eosinophilic Esophagitis Drug Product Offered
12.8.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Dr. Falk Pharma Latest Developments
12.9 Calypso
12.9.1 Company Information
12.9.2 Eosinophilic Esophagitis Drug Product Offered
12.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Calypso Latest Developments
12.10 Quorum Innovations
12.10.1 Company Information
12.10.2 Eosinophilic Esophagitis Drug Product Offered
12.10.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Quorum Innovations Latest Developments
12.11 Regeneron
12.11.1 Company Information
12.11.2 Eosinophilic Esophagitis Drug Product Offered
12.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Regeneron Latest Developments

13 Research Findings and Conclusion



★調査レポート[世界の好酸球性食道炎薬市場2020-2025:ブデソニド、フルチカゾン、その他] (コード:LPI20AP4955)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の好酸球性食道炎薬市場2020-2025:ブデソニド、フルチカゾン、その他]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆